# Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy

> **NCT00980746** · PHASE2 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 557 (actual)

## Conditions studied

- Painful Diabetic Neuropathy

## Interventions

- **DRUG:** Eslicarbazepine acetate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00980746
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11
- **Primary completion:** 2008-11
- **Final completion:** 2008-11
- **Target enrollment:** 557 (ACTUAL)
- **Last updated:** 2016-06-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00980746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00980746, "Efficacy and Safety of Eslicarbazepine Acetate as Therapy for Patients With Painful Diabetic Neuropathy". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00980746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*